Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-448 in Middle-aged and Older Men With Low Testosterone
NCT02381288Phase 2Terminated
- Sponsor
- Takeda
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of TAK-448 in Hypogonadism (4 arms), sponsored by Takeda. Primary endpoints: Percent Change From Baseline in Average Serum Concentration (Cav) of Total Serum Testosterone at Day 36 and Trough Serum Concentration of Serum Testosterone at Day 36. Started Sep 2015; status: terminated.
02
Drugs
TAK-448
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT02381288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381288.